Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Oct 15;9:4275. doi: 10.1038/s41467-018-06676-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — DREBIC reveals genotype-specific MEK inhibitor sensitivity. a Box plot showing DREBIC scores for the responder and non-responder lung cancer cell lines to MEK inhibitor (PD-0325901). b Scatter plot showing a correlation between DREBIC score and log IC₅₀ growth inhibition values of PD-0325901 MEK inhibitor. Cell lines with KRAS mutations are displayed as green dots and cells with RB1 mutations are displayed as magenta dots. c Box plots show the DREBIC score and log IC₅₀ growth inhibition due to PD-0325901 treatment in KRAS WT (gray) and KRAS mutant (green) CGP cancer cell lines. The difference in drug response and DREBIC scores between these two groups has been defined as a difference between medians (∆DREBIC and ∆log IC₅₀). d The same analysis as performed in (c) has been carried out for RB1 WT and RB1 mutant cells. e Bar plot shows the difference in DREBIC score (∆DREBIC) between WT cell lines and mutant cell lines with indicated genes. The significance of the difference was calculated by double-sided t-test and p values are shown with dots on the right side of the panel. Bars with statistically significant differences are marked with magenta and green. f Bar plot shows the difference in median log IC₅₀ scores of PD-0325901 MEK inhibitor drug response (∆Log IC₅₀) in WT cell lines and cells with mutations in the indicated genes. The significance of the difference has been calculated as in (e) and p values are shown with dots on the right side of the panel. Bars with statistically significant differences are marked with magenta for positive difference and green for the negative difference. g Box plots showing the DREBIC score and log IC₅₀ growth inhibition due to PD-0325901 treatment in BRAF WT (gray) and mutant (green) CGP cell lines. Significance assessed by Kolmogorov–Smirnov test for all panels except (b). In the box plots, bounds of the box spans from 25 to 75% percentile, center line represents median, and whiskers visualize 5 and 95% of the data points. Significance is defined as: **p < 0.01, ***p < 0.001